By a News Reporter-Staff News Editor at Pharma Business Week -- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead's cash tender offer for Kite expired at 11:59 p.m. on September 25, 2017 (see also Biotechnology Companies).
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170926005682/en/
On September 8, 2017, Gilead and Kite filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice.
Keywords for this news article include: Gilead Sciences Inc., Biotechnology Companies, Biopharmaceutical Companies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
(c) 2017 NewsRx LLC, source Health Newsletters